<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629326</url>
  </required_header>
  <id_info>
    <org_study_id>WL12-GI</org_study_id>
    <nct_id>NCT04629326</nct_id>
  </id_info>
  <brief_title>PD-L1 Targeting Molecular Imaging of Gastrointestinal Tumors</brief_title>
  <official_title>PD-L1 Targeting Molecular Imaging of Gastrointestinal Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to constrcut a noninvasive approach 68Ga-WL12 PET/CT to detect&#xD;
      the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to&#xD;
      identify patients benefiting from anti-PD-1/L1 treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value（SUV）</measure>
    <time_frame>2 years</time_frame>
    <description>The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastrointestinal Tumors</condition>
  <arm_group>
    <arm_group_label>Imaging cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>68Ga-WL12 PET/CT</intervention_name>
    <description>WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning</description>
    <arm_group_label>Imaging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Aged &gt;18 years old; ECOG 0 or 1;&#xD;
&#xD;
          -  2. Patients with Gastrointestinal tumors;&#xD;
&#xD;
          -  3. Has at least one measurable target lesion according to Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST V1.1);&#xD;
&#xD;
          -  4. life expectancy &gt;=12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Significant hepatic or renal dysfunction;&#xD;
&#xD;
          -  2. Is pregnant or ready to pregnant;&#xD;
&#xD;
          -  3. Cannot keep their states for half an hour;&#xD;
&#xD;
          -  4. Refusal to join the clinical study;&#xD;
&#xD;
          -  5. Suffering from claustrophobia or other mental diseases;&#xD;
&#xD;
          -  6. Any other situation that researchers think it is not suitable to participate in the&#xD;
             experiment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Zhu</last_name>
    <phone>010-88196495</phone>
    <email>zhuhuabch@pku.edu.cn</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

